Pharmacological treatment of migraine: Drug classes, mechanisms of action, clinical trials and new treatments.
5-HT
CGRP
clinical trials
migraine
migraine acute treatment
migraine chronic treatment
Journal
British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
revised:
28
07
2021
received:
15
01
2021
accepted:
02
08
2021
pubmed:
12
8
2021
medline:
15
3
2022
entrez:
11
8
2021
Statut:
ppublish
Résumé
Migraine is the sixth most prevalent disease globally, a major cause of disability, and it imposes an enormous personal and socio-economic burden. Migraine treatment is often limited by insufficient therapy response, leading to the need for individually adjusted treatment. In this review, we analyse historical and current pharmaceutical development approaches in acute and chronic migraine based on a comprehensive and systematic analysis of Food and Drug Administration (FDA)-approved drugs and those under investigation. The development of migraine therapeutics has significantly intensified during the last 3 years, as shown by our analysis of the trends of drug development between 1970 and 2020. The spectrum of drug targets has expanded considerably, which has been accompanied by an increase in the number of specialised clinical trials. This review highlights the mechanistic implications of FDA-approved and currently investigated drugs and discusses current and future therapeutic options based on identified drug classes of interest.
Substances chimiques
Pharmaceutical Preparations
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
4588-4607Informations de copyright
© 2021 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
Ailani, J., Lipton, R. B., Hutchinson, S., Knievel, K., Lu, K., Butler, M., Yu, S. Y., Finnegan, M., Severt, L., & Trugman, J. M. (2020). Long-term safety evaluation of ubrogepant for the acute treatment of migraine: Phase 3, randomized, 52-week extension trial. Headache, 60(1), 141-152. https://doi.org/10.1111/head.13682
Akerman, S., & Goadsby, P. J. (2005). Topiramate inhibits trigeminovascular activation: An intravital microscopy study. British Journal of Pharmacology, 146(1), 7-14. https://doi.org/10.1038/sj.bjp.0706290
Akopian, A. N., Chen, C. C., Ding, Y., Cesare, P., & Wood, J. N. (2000). A new member of the acid-sensing ion channel family. Neuroreport, 11(10), 2217-2222. https://doi.org/10.1097/00001756-200007140-00031
Alexander, S. P. H., Christopoulos, A., Davenport, A. P., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., & Pawson, A. J. (2019). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology, 176, S21-S141. https://doi.org/10.1111/bph.14748
Alexander, S. P. H., Fabbro, D., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., & Southan, C. (2019). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes. British Journal of Pharmacology, 176, S297-S396. https://doi.org/10.1111/bph.14752
Alexander, S. P. H., Mathie, A., Peters, J. A., Veale, E. L., Striessnig, J., Kelly, E., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., & Sharman, J. L. (2019). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels. British Journal of Pharmacology, 176, S142-S228. https://doi.org/10.1111/bph.14749
Amery, W. K. (1987). The oxygen theory of migraine. In J. N. Blau (Ed.), Migraine: Clinical, therapeutic, conceptual and research aspects (pp. 403-431). Chapman & Hall.
Ansell, E., Fazzone, T., Festenstein, R., Johnson, E. S., Thavapalan, M., Wilkinson, M., & Wozniak, I. (1988). Nimodipine in migraine prophylaxis. Cephalalgia, 8(4), 269-272. https://doi.org/10.1046/j.1468-2982.1988.0804269.x
Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Southan, C., Sharman, J. L., Campo, B., Cavanagh, D. R., Alexander, S. P. H., Davenport, A. P., Spedding, M., Davies, J. A., & NC-IUPHAR. (2019). The IUPHAR/BPS Guide to PHARMACOLOGY in 2020: Extending immunopharmacology content and introducing the IUPHAR/MMV Guide to MALARIA PHARMACOLOGY. Nucleic Acids Research, 48(D1), D1006-D1021. https://doi.org/10.1093/nar/gkz951
Artemenko, A. R., Kurenkov, A. L., Filatova, E. G., Nikitin, S. S., Kaube, H., & Katsarava, Z. (2008). Effects of topiramate on migraine frequency and cortical excitability in patients with frequent migraine. Cephalalgia, 28(3), 203-208. https://doi.org/10.1111/j.1468-2982.2007.01491.x
Attwood, M. M., Jonsson, J., Rask-Andersen, M., & Schiöth, H. B. (2020). Soluble ligands as drug targets. Nature Reviews Drug Discovery, 19(10), 695-710. https://doi.org/10.1038/s41573-020-0078-4
Attwood, M. M., Rask-Andersen, M., & Schiöth, H. B. (2018). Orphan drugs and their impact on pharmaceutical development. Trends in Pharmacological Sciences, 39(6), 525-535. https://doi.org/10.1016/j.tips.2018.03.003 Erratum in: Trends in Pharmacological Sciences, 2018 Dec, 39(12), 1077.
Aurora, S. K., Dodick, D. W., Turkel, C. C., DeGryse, Silberstein, S. D., Lipton, R. B., Diener, H. C., Brin, M. F., & PREEMPT 1 Chronic Migraine Study Group. (2010). OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia, 30(7), 793-803. https://doi.org/10.1177/0333102410364676
Avcu, N., Doğan, N. Ö., Pekdemir, M., Yaka, E., Yılmaz, S., Alyeşil, C., & Akalın, L. E. (2017). Intranasal lidocaine in acute treatment of migraine: A randomized controlled trial. Annals of Emergency Medicine, 69(6), 743-751. https://doi.org/10.1016/j.annemergmed.2016.09.031
Bartsch, T., & Goadsby, P. J. (2002). Stimulation of the greater occipital nerve induces increased central excitability of dural afferent input. Brain, 125(7), 1496-1509. https://doi.org/10.1093/brain/awf166
Benemei, S., De Cesaris, F., Fusi, C., Rossi, E., Lupi, C., & Geppetti, P. (2013). TRPA1 and other TRP channels in migraine. The Journal of Headache and Pain, 14(1), 71. https://doi.org/10.1186/1129-2377-14-71
Bolay, H., Reuter, U., Dunn, A. K., Huang, Z., Boas, D. A., & Moskowitz, M. A. (2002). Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nature Medicine, 8(2), 136-142. https://doi.org/10.1038/nm0202-136
Burstein, R., Noseda, R., & Borsook, D. (2015). Migraine: Multiple processes, complex pathophysiology. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 35(17), 6619-6629. https://doi.org/10.1523/JNEUROSCI.0373-15.2015
Burstein, R., Zhang, X., Levy, D., Aoki, K. R., & Brin, M. F. (2014). Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains. Cephalalgia, 34(11), 853-869. https://doi.org/10.1177/0333102414527648
Cadiou, H., Studer, M., Jones, N. G., Smith, E. S., Ballard, A., McMahon, S. B., & McNaughton, P. A. (2007). Modulation of acid-sensing ion channel activity by nitric oxide. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience., 27(48), 13251-13260. https://doi.org/10.1523/JNEUROSCI.2135-07.2007
Caviness, V. S. Jr., & O'Brien, P. (1980). Current concepts. Headache. The New England Journal of Medicine, 302(8), 446-450. https://doi.org/10.1056/NEJM198002213020806
Charles, A. (2013). The evolution of a migraine attack-A review of recent evidence. Headache, 53(2), 413-419. https://doi.org/10.1111/head.12026
Conway, C. M., Croop, R., Dubowchik, G. M., Coric, V., & Lipton, R. B. (2019). Cardiovascular safety of rimegepant 75 mg in 3 randomized clinical trials and systematic evaluations from in vitro, ex vivo, and in vivo nonclinical assays. Retrieved from https://www.biohavenpharma.com/sites/default/files/documents/rimegepant-cv-safety-2019-ahs.pdf
Coppola, G., Di Renzo, A., Tinelli, E., Di Lorenzo, C., Di Lorenzo, G., Parisi, V., Serrao, M., Schoenen, J., & Pierelli, F. (2016). Thalamo-cortical network activity during spontaneous migraine attacks. Neurology, 87(20), 2154-2160. https://doi.org/10.1212/WNL.0000000000003327
Croop, R., Ivans, A., Stock, D., Hould, J., Morris, B. A., Stringfellow, J., Jensen, C. M., Moulin, J. A., Larouche, R., Tanguay, M., & Coric, V. (2018). A phase 1 study to evaluate the bioequivalence of oral tablet and orally dissolving tablet formulations of rimegepant, a small molecule CGRP receptor antagonist. Retrieved from https://www.biohavenpharma.com/sites/default/files/documents/Rimegepant-Zydis-ODT-Bioequivalence-Phase-1-Study_AHS-2018-Late-Breaking-Poster-Presentation-1.pdf
Cuadrado, M. L., Aledo-Serrano, Á., Navarro, P., López-Ruiz, P., Fernández-de-Las-Peñas, C., González-Suárez, I., Orviz, A., & Fernández-Pérez, C. (2017). Short-term effects of greater occipital nerve blocks in chronic migraine: A double-blind, randomised, placebo-controlled clinical trial. Cephalalgia, 37(9), 864-872. https://doi.org/10.1177/0333102416655159
Cutrer, F. M., Limmroth, V., & Moskowitz, M. A. (1997). Possible mechanisms of valproate in migraine prophylaxis. Cephalalgia, 17(2), 93-100. https://doi.org/10.1046/j.1468-2982.1997.1702093.x
Dakhale, G. N., Sharma, V. S., Thakre, M. N., & Kalikar, M. (2019). Low-dose sodium valproate versus low-dose propranolol in prophylaxis of common migraine headache: A randomized, prospective, parallel, open-label study. Indian Journal of Pharmacology, 51(4), 255-262. https://doi.org/10.4103/ijp.IJP_457_18
Denuelle, M., Fabre, N., Payoux, P., Chollet, F., & Geraud, G. (2007). Hypothalamic activation in spontaneous migraine attacks. Headache, 47(10), 1418-1426. https://doi.org/10.1111/j.1526-4610.2007.00776.x
Depre, C., Antalik, L., Starling, A., Koren, M., Eisele, O., Lenz, R. A., & Mikol, D. D. (2018). A randomized, double-blind, placebo-controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina. Headache, 58(5), 715-723. https://doi.org/10.1111/head.13316
Derry, C. J., Derry, S., & Moore, R. A. (2014). Sumatriptan (all routes of administration) for acute migraine attacks in adults-Overview of Cochrane reviews. The Cochrane Database of Systematic Reviews, 2014(5), CD009108. https://doi.org/10.1002/14651858.CD009108.pub2
Diener, H. C., Dodick, D. W., Aurora, S. K., Turkel, C. C., DeGryse, R. E., Lipton, R. B., Silberstein, S. D., Brin, M. F., & PREEMPT 2 Chronic Migraine Study Group. (2010). OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia, 30(7), 804-814. https://doi.org/10.1177/0333102410364677
Diener, H. C., Matias-Guiu, J., Hartung, E., Pfaffenrath, V., Ludin, H., Nappi, G., & de Beukelaar, F. (2002). Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: A comparison with propranolol 160 mg daily. Cephalalgia, 22(3), 209-221. https://doi.org/10.1046/j.1468-2982.2002.t01-1-00309.x
Do, T. P., Guo, S., & Ashina, M. (2019). Therapeutic novelties in migraine: New drugs, new hope? The Journal of Headache and Pain, 20, 37. https://doi.org/10.1186/s10194-019-0974-3
Dodick, D. W. (2004). Indomethacin-responsive headache syndromes. Current Pain and Headache Reports, 8(1), 19-26. https://doi.org/10.1007/s11916-004-0036-6
Dodick, D. W., Freitag, F., Banks, J., Saper, J., Xiang, J., Rupnow, M., Greenberg, S. J., Hulihan, J., & CAPSS-277 Investigator Group. (2009). Topiramate versus amitriptyline in migraine prevention: A 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clinical Therapeutics, 31(3), 542-559. https://doi.org/10.1016/j.clinthera.2009.03.020
Dohi, Y., Ohashi, M., Sugiyama, M., Takase, H., Sato, K., & Ueda, R. (2003). Candesartan reduces oxidative stress and inflammation in patients with essential hypertension. Hypertension Research: Official Journal of the Japanese Society of Hypertension, 26(9), 691-697. https://doi.org/10.1291/hypres.26.691
Durley, Y., Cubberley, R. B., & Thomas, S. (1981). Antihypertensive effect of oral timolol maleate and hydrochlorothiazide once daily compared with hydrochlorothiazide once daily. American Journal of Hospital Pharmacy, 38(8), 1161-1164.
Dussor, G. (2014). Serotonin, 5HT1 agonists, and migraine: New data, but old questions still not answered. Current Opinion in Supportive and Palliative Care, 8(2), 137-142. https://doi.org/10.1097/SPC.0000000000000044
Dussor, G. (2015). ASICs as therapeutic targets for migraine. Neuropharmacology, 94, 64-71. https://doi.org/10.1016/j.neuropharm.2014.12.015
Edvinsson, L. (2017). The trigeminovascular pathway: Role of CGRP and CGRP receptors in migraine. Headache: The Journal of Head and Face Pain, 57(Suppl. 2), 47-55. https://doi.org/10.1111/head.13081
Edvinsson, L., Haanes, K. A., Warfvinge, K., & Krause, D. N. (2018). CGRP as the target of new migraine therapies-Successful translation from bench to clinic. Nature Reviews Neurology, 14(6), 338-350. https://doi.org/10.1038/s41582-018-0003-1
Edvinsson, L., & Linde, M. (2010). New drugs in migraine treatment and prophylaxis: Telcagepant and topiramate. Lancet, 376(9741), 645-655. https://doi.org/10.1016/S0140-6736(10)60323-6
Evers, S., Afra, J., Frese, A., Goadsby, P. J., Linde, M., May, A., Sándor, P. S., & European Federation of Neurological Societies. (2009). EFNS guideline on the drug treatment of migraine-Revised report of an EFNS task force. European Journal of Neurology, 16(9), 968-981. https://doi.org/10.1111/j.1468-1331.2009.02748.x
Ferrari, M. D., Goadsby, P. J., Roon, K. I., & Lipton, R. B. (2002). Triptans (serotonin, 5-HT1B/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia, 22(8), 633-658. https://doi.org/10.1046/j.1468-2982.2002.00404.x
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. (2017). Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. The Lancet, 390(10100), 1211-1259. https://doi.org/10.1016/S0140-6736(17)32154-2
Giffin, N. J., Ruggiero, L., Lipton, R. B., Silberstein, S. D., Tvedskov, J. F., Olesen, J., Altman, J., Goadsby, P. J., & Macrae, A. (2003). Premonitory symptoms in migraine: An electronic diary study. Neurology, 60(6), 935-940. https://doi.org/10.1212/01.wnl.0000052998.58526.a9
Goadsby, P. J., & Classey, J. D. (2003). Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience, 122(2), 491-498. https://doi.org/10.1016/s0306-4522(03)00570-0
Goadsby, P. J., Dodick, D. W., Ailani, J., Trugman, J. M., Finnegan, M., Lu, K., & Szegedi, A. (2020). Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: A double-blind, randomised phase 2b/3 trial. The Lancet. Neurology., 19(9), 727-737. https://doi.org/10.1016/S1474-4422(20)30234-9
Goadsby, P. J., Edvinsson, L., & Ekman, R. (1990). Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Annals of Neurology, 28(2), 183-187. https://doi.org/10.1002/ana.410280213
Goadsby, P. J., Holland, P. R., Martins-Oliveira, M., Hoffmann, J., Schankin, C., & Akerman, S. (2017). Pathophysiology of migraine: A disorder of sensory processing. Physiological Reviews, 97(2), 553-622. https://doi.org/10.1152/physrev.00034.2015
Goadsby, P. J., Reuter, U., Hallström, Y., Broessner, G., Bonner, J. H., Zhang, F., Sapra, S., Picard, H., Mikol, D. D., & Lenz, R. A. (2017). A controlled trial of erenumab for episodic migraine. The New England Journal of Medicine, 377(22), 2123-2132. https://doi.org/10.1056/NEJMoa1705848
Goadsby, P. J., Wietecha, L. A., Dennehy, E. B., Kuca, B., Case, M. G., Aurora, S. K., & Gaul, C. (2019). Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain, 142(7), 1894-1904. https://doi.org/10.1093/brain/awz134
Groth, W., Blume, A., Gohlke, P., Unger, T., & Culman, J. (2003). Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats. Journal of Hypertension, 21(11), 2175-2182. https://doi.org/10.1097/00004872-200311000-00028
Harriott, A. M., Takizawa, T., Chung, D. Y., & Chen, S. P. (2019). Spreading depression as a preclinical model of migraine. The Journal of Headache and Pain, 20(1), 45. https://doi.org/10.1186/s10194-019-1001-4
Hay, D. L. (2019). CGRP receptor biology: Is there more than one receptor? Handbook of Experimental Pharmacology, 255, 13-22. https://doi.org/10.1007/164_2018_131
Hay, D. L., Garelja, M. L., Poyner, D. R., & Walker, C. S. (2018). Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25. British Journal of Pharmacology, 175(1), 3-17. https://doi.org/10.1111/bph.14075
Headache Classification Committee of the International Headache Society (IHS). (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38(1), 1-211. https://doi.org/10.1177/0333102417738202
Herd, C. P., Tomlinson, C. L., Rick, C., Scotton, W. J., Edwards, J., Ives, N., Clarke, C. E., & Sinclair, A. (2018). Botulinum toxins for the prevention of migraine in adults. The Cochrane Database of Systemic Reviews, 6(6), CD011616. https://doi.org/10.1002/14651858.CD011616.pub2
Hesselager, M., Timmermann, D. B., & Ahring, P. K. (2004). pH dependency and desensitization kinetics of heterologously expressed combinations of acid-sensing ion channel subunits. The Journal of Biological Chemistry, 279(12), 11006-11015. https://doi.org/10.1074/jbc.M313507200
Hill, R. G., & Salt, T. E. (1982). An ionophoretic study of the responses of rat caudal trigeminal nucleus neurones to non-noxious mechanical sensory stimuli. The Journal of Physiology, 327, 65-78. https://doi.org/10.1113/jphysiol.1982.sp014220
Ho, T. W., Connor, K. M., Zhang, Y., Pearlman, E., Koppenhaver, J., Fan, X., Lines, C., Edvinsson, L., Goadsby, P. J., & Michelson, D. (2014). Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology, 83(11), 958-966. https://doi.org/10.1212/WNL.0000000000000771
Hoffmann, U., Sukhotinsky, I., Eikermann-Haerter, K., & Ayata, C. (2013). Glucose modulation of spreading depression susceptibility. Journal of Cerebral Blood Flow & Metabolism, 33(2), 191-195. https://doi.org/10.1038/jcbfm.2012.132
Holton, C. M., Strother, L. C., Dripps, I., Pradhan, A. A., Goadsby, P. J., & Holland, P. R. (2020). Acid-sensing ion channel 3 blockade inhibits durovascular and nitric oxide-mediated trigeminal pain. British Journal of Pharmacology, 177(11), 2478-2486. https://doi.org/10.1111/bph.14990
Iacobucci, G. J., Visnjevac, O., Pourafkari, L., & Nader, N. D. (2017). Ketamine: An update on cellular and subcellular mechanisms with implications for clinical practice. Pain Physician, 20(2), E285-E301.
Johnson, K. W., Schaus, J. M., Durkin, M. M., Audia, J. E., Kaldor, S. W., Flaugh, M. E., Adham, N., Zgombick, J. M., Cohen, M. L., Branchek, T. A., & Phebus, L. A. (1997). 5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. Neuroreport, 8(9-10), 2237-2240. https://doi.org/10.1097/00001756-199707070-00029
Karatas, H., Erdener, S. E., Gursoy-Ozdemir, Y., Lule, S., Eren-Koçak, E., Sen, Z. D., & Dalkara, T. (2013). Spreading depression triggers headache by activating neuronal Panx1 channels. Science, 339(6123), 1092-1095. https://doi.org/10.1126/science.1231897
Karsan, N., Gonzales, E. B., & Dussor, G. (2018). Targeted acid-sensing ion channel therapies for migraine. Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics, 15(2), 402-414. https://doi.org/10.1007/s13311-018-0619-2
Karsan, N., Palethorpe, D., Rattanawong, W., Marin, J. C., Bhola, R., & Goadsby, P. J. (2018). Flunarizine in migraine-related headache prevention: Results from 200 patients treated in the UK. European Journal of Neurology, 25(6), 811-817. https://doi.org/10.1111/ene.13621
Karsan, N., Prabhakar, P., & Goadsby, P. J. (2016). Characterising the premonitory stage of migraine in children: A clinic-based study of 100 patients in a specialist headache service. The Journal of Headache and Pain, 17(1), 94. https://doi.org/10.1186/s10194-016-0689-7
Kashipazha, D., Nakhostin-Mortazavi, A., Mohammadianinejad, S. E., Bahadoram, M., Zandifar, S., & Tarahomi, S. (2014). Preventive effect of greater occipital nerve block on severity and frequency of migraine headache. Global Journal of Health Science, 6(6), 209-213. https://doi.org/10.5539/gjhs.v6n6p209
Kelman, L. (2007). The triggers or precipitants of the acute migraine attack. Cephalalgia, 27(5), 394-402. https://doi.org/10.1111/j.1468-2982.2007.01303.x
Khazaei, M., Hosseini Nejad Mir, N., Yadranji Aghdam, F., Taheri, M., & Ghafouri-Fard, S. (2019). Effectiveness of intravenous dexamethasone, metoclopramide, ketorolac, and chlorpromazine for pain relief and prevention of recurrence in the migraine headache: A prospective double-blind randomized clinical trial. Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 40(5), 1029-1033. https://doi.org/10.1007/s10072-019-03766-x
Labastida-Ramírez, A., Rubio-Beltrán, E., Haanes, K. A., Chan, K. Y., Garrelds, I. M., Johnson, K. W., Danser, A. H. J., Villalón, C. M., & MaassenVanDenBrink, A. (2020). Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system. Pain, 161(5), 1092-1099. https://doi.org/10.1097/j.pain.0000000000001801
Lapidus, K. A., Levitch, C. F., Perez, A. M., Brallier, J. W., Parides, M. K., Soleimani, L., Feder, A., losifescu, D. V., Charney, D. S., & Murrough, J. W. (2014). A randomized controlled trial of intranasal ketamine in major depressive disorder. Biological Psychiatry, 76(12), 970-976. https://doi.org/10.1016/j.biopsych.2014.03.026
Lassen, L. H., Haderslev, P. A., Jacobsen, V. B., Iversen, H. K., Sperling, B., & Olesen, J. (2002). CGRP may play a causative role in migraine. Cephalalgia, 22(1), 54-61. https://doi.org/10.1046/j.1468-2982.2002.00310.x
Lauritsen, C., Mazuera, S., Lipton, R. B., & Ashina, S. (2016). Intravenous ketamine for subacute treatment of refractory chronic migraine: A case series. The Journal of Headache and Pain, 17(1), 106. https://doi.org/10.1186/s10194-016-0700-3
Lauritzen, M., & Hansen, A. J. (1992). The effect of glutamate receptor blockade on anoxic depolarization and cortical spreading depression. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism, 12(2), 223-229. https://doi.org/10.1038/jcbfm.1992.32
Lazreg, S., Merad, Z., Nouri, M. T., Garout, R., Derdour, A., Ghroud, N., Kherroubi, R., Meziane, M., Belkacem, S., Ouhadj, O., Baudouin, C., & Tiar, M. (2018). Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications. Journal Français d'Ophtalmologie, 41(10), 945-954. https://doi.org/10.1016/j.jfo.2018.04.012
Leo, A. A. P., & Morison, R. S. (1945). Propagation of spreading cortical depression. Journal of Neurophysiology, 8(1), 33-45. https://doi.org/10.1152/jn.1945.8.1.33
Linde, M., Gustavsson, A., Stovner, L. J., Steiner, T. J., Barré, J., Katsarava, Z., Lainez, J. M., Lampl, C., Lantéri-Minet, M., Rastenyte, D., Ruiz de la Torre, E., Tassorelli, C., & Andrée, C. (2012). The cost of headache disorders in Europe: The Eurolight project. European Journal of Neurology, 19(5), 703-711. https://doi.org/10.1111/j.1468-1331.2011.03612.x
Linde, M., Mulleners, W. M., Chronicle, E. P., & McCrory, D. C. (2013a). Antiepileptics other than gabapentin, pregabalin, topiramate, and valproate for the prophylaxis of episodic migraine in adults. The Cochrane Database of Systematic Reviews, 6, CD010608. https://doi.org/10.1002/14651858.CD010608
Linde, M., Mulleners, W. M., Chronicle, E. P., & McCrory, D. C. (2013b). Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database of Systematic Reviews, 2013(6), CD010610. https://doi.org/10.1002/14651858.CD010610
Lipton, R. B., Goldstein, J., Baggish, J. S., Yataco, A. R., Sorrentino, J. V., & Quiring, J. N. (2005). Aspirin is efficacious for the treatment of acute migraine. Headache, 45(4), 283-292. https://doi.org/10.1111/j.1526-4610.2005.05065.x
Louis, P. (1981). A double-blind placebo-controlled prophylactic study of flunarizine (Sibelium®) in migraine. Headache, 21(6), 235-239. https://doi.org/10.1111/j.1526-4610.1981.hed2106235.x
Ma, Q. P., Hill, R., & Sirinathsinghji, D. (2001). Colocalization of CGRP with 5-HT1B/1D receptors and substance P in trigeminal ganglion neurons in rats. The European Journal of Neuroscience, 13(11), 2099-2104. https://doi.org/10.1046/j.0953-816x.2001.01586.x
MaassenVanDenBrink, A., Meijer, J., Villalón, C. M., & Ferrari, M. D. (2016). Wiping out CGRP: Potential cardiovascular risks. Trends in Pharmacological Sciences, 37(9), 779-788. https://doi.org/10.1016/j.tips.2016.06.002
Maizels, M., & Geiger, A. M. (1999). Intranasal lidocaine for migraine: A randomized trial and open-label follow-up. Headache, 39(8), 543-551. https://doi.org/10.1046/j.1526-4610.1999.3908543.x
Mamet, J., Baron, A., Lazdunski, M., & Voilley, N. (2002). Proinflammatory mediators, stimulators of sensory neuron excitability via the expression of acid-sensing ion channels. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 22(24), 10662-10670. https://doi.org/10.1523/JNEUROSCI.22-24-10662.2002
Maniyar, F. H., Sprenger, T., Monteith, T., Schankin, C., & Goadsby, P. J. (2014). Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain, 137(1), 232-241. https://doi.org/10.1093/brain/awt320
Manoukian, R., Sun, H., Miller, S., Shi, D., Chan, B., & Xu, C. (2019). Effects of monoclonal antagonist antibodies on calcitonin gene-related peptide receptor function and trafficking. The Journal of Headache and Pain, 20(1), 44. https://doi.org/10.1186/s10194-019-0992-1
Marcus, R., Goadsby, P. J., Dodick, D., Stock, D., Manos, G., & Fischer, T. Z. (2014). BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia, 34(2), 114-125. https://doi.org/10.1177/0333102413500727
Markowitz, S., Saito, K., & Moskowitz, M. A. (1987). Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. Journal of Neuroscience, 7(12), 4129-4136. https://doi.org/10.1523/JNEUROSCI.07-12-04129.1987
Martella, G., Costa, C., Pisani, A., Cupini, L. M., Bernardi, G., & Calabresi, P. (2008). Antiepileptic drugs on calcium currents recorded from cortical and PAG neurons: Therapeutic implications for migraine. Cephalalgia, 28(12), 1315-1326. https://doi.org/10.1111/j.1468-2982.2008.01682.x
McLean, M. J., Bukhari, A. A., & Wamil, A. W. (2000). Effects of topiramate on sodium-dependent action-potential firing by mouse spinal cord neurons in cell culture. Epilepsia, 41(S1), 21-24. https://doi.org/10.1111/j.1528-1157.2000.tb02166.x
Melo-Carrillo, A., Noseda, R., Nir, R. R., Schain, A. J., Stratton, J., Strassman, A. M., & Burstein, R. (2017). Selective inhibition of trigeminovascular neurons by fremanezumab: A humanized monoclonal anti-CGRP antibody. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 37(30), 7149-7163. https://doi.org/10.1523/JNEUROSCI.0576-17.2017
Misra, U. K., Jose, M., & Kalita, J. (2004). Rofecoxib versus ibuprofen for acute treatment of migraine: A randomised placebo controlled trial. Postgraduate Medical Journal, 80(950), 720-723. https://doi.org/10.1136/pgmj.2003.012393
Mizuno, K., Niimura, S., Tani, M., Saito, I., Sanada, H., Takahashi, M., Okazaki, K., Yamaguchi, M., & Fukuchi, S. (1992). Hypotensive activity of TCV-116, a newly developed angiotensin II receptor antagonist, in spontaneously hypertensive rats. Life Sciences, 51(20), PL183-PL187. https://doi.org/10.1016/0024-3205(92)90627-2
Morgan, T. (2003). Renin, angiotensin, sodium and organ damage. Hypertension Research: Official Journal of the Japanese Society of Hypertension, 26(5), 349-354. https://doi.org/10.1291/hypres.26.349
Motov, S., Rockoff, B., Cohen, V., Pushkar, I., Likourezos, A., McKay, C., Soleyman-Zomalan, E., Homel, P., Terentiev, V., & Fromm, C. (2015). Intravenous subdissociative-dose ketamine versus morphine for analgesia in the emergency department: A randomized controlled trial. Annals of Emergency Medicine, 66, 222-229.e1. https://doi.org/10.1016/j.annemergmed.2015.03.004
Munkholm, T. K., & Arendt-Nielsen, L. (2017). The interaction between NGF-induced hyperalgesia and acid-provoked pain in the infrapatellar fat pad and tibialis anterior muscle of healthy volunteers. European Journal of Pain (London, England), 21(3), 474-485. https://doi.org/10.1002/ejp.941
Noseda, R., Bernstein, C. A., Nir, R. R., Lee, A. J., Fulton, A. B., Bertisch, S. M., Hovaguimian, A., Cestari, D. M., Saavedra-Walker, R., Borsook, D., Doran, B. L., Buettner, C., & Burstein, R. (2016). Migraine photophobia originating in cone-driven retinal pathways. Brain: A Journal of Neurology, 139(7), 1971-1986. https://doi.org/10.1093/brain/aww119
Olesen, J., Diener, H. C., Husstedt, I. W., Goadsby, P. J., Hall, D., Meier, U., Pollentier, S., Lesko, L. M., & BIBN 4096 BS Clinical Proof of Concept Study Group. (2004). Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. The New England Journal of Medicine, 350(11), 1104-1110. https://doi.org/10.1056/NEJMoa030505
Olesen, J., Lauritzen, M., Tfelt-Hansen, P., Henriksen, L., & Larsen, B. (1982). Spreading cerebral oligemia in classical- and normal cerebral blood flow in common migraine. Headache, 22(6), 242-248. https://doi.org/10.1111/j.1526-4610.1982.hed2206242.x
Oswald, J. C., & Schuster, N. M. (2018). Lasmiditan for the treatment of acute migraine: A review and potential role in clinical practice. Journal of Pain Research, 11, 2221-2227. https://doi.org/10.2147/JPR.S152216
Owada, K. (2004). Efficacy of candesartan in the treatment of migraine in hypertensive patients. Hypertension Research: Official Journal of the Japanese Society of Hypertension, 27(6), 441-446. https://doi.org/10.1291/hypres.27.441
Parikh, S. K., & Silberstein, S. D. (2019). Current status of antiepileptic drugs as preventive migraine therapy. Current Treatment Options in Neurology, 21(4), 16. https://doi.org/10.1007/s11940-019-0558-1
Parsons, C. G., Danysz, W., & Quack, G. (1999). Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist-A review of preclinical data. Neuropharmacology, 38(6), 735-767. https://doi.org/10.1016/s0028-3908(99)00019-2
Pietrobon, D., & Moskowitz, M. A. (2013). Pathophysiology of migraine. Annual Review of Physiology, 75, 365-391. https://doi.org/10.1146/annurev-physiol-030212-183717
Pietrobon, D., & Moskowitz, M. A. (2014). Chaos and commotion in the wake of cortical spreading depression and spreading depolarizations. Nature Reviews Neuroscience, 15(6), 379-393. https://doi.org/10.1038/nrn3770
Piilgaard, H., & Lauritzen, M. (2009). Persistent increase in oxygen consumption and impaired neurovascular coupling after spreading depression in rat neocortex. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism, 29(9), 1517-1527. https://doi.org/10.1038/jcbfm.2009.73
Pisanu, C., Lundin, E., Preisig, M., Gholam-Rezaee, M., Castelao, E., Pistis, G., Merikangas, K. R., Glaus, J., Squassina, A., del Zompo, M., Schiöth, H. B., & Mwinyi, J. (2020). Major depression subtypes are differentially associated with migraine subtype, prevalence and severity. Cephalalgia, 40(4), 347-356. https://doi.org/10.1177/0333102419884935
Pisanu, C., Preisig, M., Castelao, E., Glaus, J., Cunningham, J. L., del Zompo, M., Merikangas, K. R., Schiöth, H. B., & Mwinyi, J. (2017). High leptin levels are associated with migraine with aura. Cephalalgia, 37(5), 435-441. https://doi.org/10.1177/0333102416648650
Pomeroy, J. L., Marmura, M. J., Nahas, S. J., & Viscusi, E. R. (2017). Ketamine infusions for treatment refractory headache. Headache, 57(2), 276-282. https://doi.org/10.1111/head.13013
Puledda, F., Goadsby, P. J., & Prabhakar, P. (2018). Treatment of disabling headache with greater occipital nerve injections in a large population of childhood and adolescent patients: A service evaluation. The Journal of Headache and Pain, 19, 5. https://doi.org/10.1186/s10194-018-0835-5
Rao, A. S., Gelaye, B., Kurth, T., Dash, P. D., Nitchie, H., & Peterlin, B. L. (2016). A randomized trial of ketorolac vs sumatripan vs placebo nasal spray (KSPN) for acute migraine. Headache, 56(2), 331-340. https://doi.org/10.1111/head.12767
Rask-Andersen, M., Almén, M. S., & Schiöth, H. B. (2011). Trends in the exploitation of novel drug targets. Nature Reviews Drug Discovery, 10(8), 579-590. https://doi.org/10.1038/nrd3478
Rask-Andersen, M., Zhang, J., Fabbro, D., & Schiöth, H. B. (2014). Advances in kinase targeting: Current clinical use and clinical trials. Trends in Pharmacological Sciences, 35(11), 604-620. https://doi.org/10.1016/j.tips.2014.09.007
Reed, K. L., Black, S. B., Banta, C. J. 2nd, & Will, K. R. (2010). Combined occipital and supraorbital neurostimulation for the treatment of chronic migraine headaches: Initial experience. Cephalalgia, 30(3), 260-271. https://doi.org/10.1111/j.1468-2982.2009.01996.x
Rizzoli, P. B. (2014). Emerging therapeutic options for acute migraine: Focus on the potential of lasmiditan. Neuropsychiatric Disease and Treatment, 10, 547-552. https://doi.org/10.2147/NDT.S25531
Russel, M. B., Rasmussen, B. K., Fenger, K., & Olesen, J. (1996). Migraine without aura and migraine with aura are distinct clinical entities: A study of four hundred and eighty-four male and female migraineurs from the general population. Cephalalgia: An International Journal of Headache, 16(4), 239-245. https://doi.org/10.1046/j.1468-2982.1996.1604239.x
Russo, A. F. (2015). Calcitonin gene-related peptide (CGRP): A new target for migraine. Annual Review of Pharmacology and Toxicology, 55, 533-552. https://doi.org/10.1146/annurev-pharmtox-010814-124701
Sánchez-Porras, R., Santos, E., Schöll, M., Stock, C., Zheng, Z., Schiebel, P., Orakcioglu, B., Unterberg, A. W., & Sakowitz, O. W. (2014). The effect of ketamine on optical and electrical characteristics of spreading depolarizations in gyrencephalic swine cortex. Neuropharmacology, 84, 52-61. https://doi.org/10.1016/j.neuropharm.2014.04.018
Schulte, L. H., Jürgens, T. P., & May, A. (2015). Photo-, osmo- and phonophobia in the premonitory phase of migraine: Mistaking symptoms for triggers? The Journal of Headache and Pain, 16, 14. https://doi.org/10.1186/s10194-015-0495-7
Scott, L. J. (2020). Ubrogepant: First approval. Drugs, 80(3), 323-328. https://doi.org/10.1007/s40265-020-01264-5 Erratum in: Drugs, 2020 Apr, 80(5), 523.
Shepheard, S., Edvinsson, L., Cumberbatch, M., Williamson, D., Mason, G., Webb, J., Boyce, S., Hill, R., & Hargreaves, R. (1999). Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370. Cephalalgia, 19(10), 851-858. https://doi.org/10.1046/j.1468-2982.1999.1910851.x
Shields, K. G., & Goadsby, P. J. (2005). Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: A role in migraine? Brain, 128(1), 86-97. https://doi.org/10.1093/brain/awh298
Silberstein, S., Saper, J., Berenson, F., Somogyi, M., McCague, K., & D'Souza, J. (2008). Oxcarbazepine in migraine headache: A double-blind, randomized, placebo-controlled study. Neurology, 70(7), 548-555. https://doi.org/10.1212/01.wnl.0000297551.27191.70
Silberstein, S. D., Dodick, D. W., Bigal, M. E., Yeung, P. P., Goadsby, P. J., Blankenbiller, T., Grozinski-Wolff, M., Yang, R., Ma, Y., & Aycardi, E. (2017). Fremanezumab for the preventive treatment of chronic migraine. The New England Journal of Medicine, 377(22), 2113-2122. https://doi.org/10.1056/NEJMoa1709038
Silberstein, S. D., & Kori, S. H. (2013). Dihydroergotamine: A review of formulation approaches for the acute treatment of migraine. CNS Drugs, 27(5), 385-394. https://doi.org/10.1007/s40263-013-0061-2
Sørensen, P. S., Hansen, K., & Olesen, J. (1986). A placebo-controlled, double-blind, cross-over trial of flunarizine in common migraine. Cephalalgia, 6(1), 7-14. https://doi.org/10.1046/j.1468-2982.1986.0601007.x
Stankewitz, A., Aderjan, D., Eippert, F., & May, A. (2011). Trigeminal nociceptive transmission in migraineurs predicts migraine attacks. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 31(6), 1937-1943. https://doi.org/10.1523/JNEUROSCI.4496-10.2011
Steen, K. H., Reeh, P. W., Anton, F., & Handwerker, H. O. (1992). Protons selectively induce lasting excitation and sensitization to mechanical stimulation of nociceptors in rat skin, in vitro. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 12(1), 86-95. https://doi.org/10.1523/JNEUROSCI.12-01-00086.1992
Stellar, S., Ahrens, S. P., Meibohm, A. R., & Reines, S. A. (1984). Migraine prevention with timolol: A double-blind crossover study. JAMA, 252(18), 2576-2580. https://doi.org/10.1001/jama.1984.03350180030025
Stephenson, M. L., & Zamecnik, P. C. (1978). Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proceedings of the National Academy of Sciences of the United States of America, 75(1), 285-288. https://doi.org/10.1073/pnas.75.1.285
Storer, R. J., Akerman, S., & Goadsby, P. J. (2004). Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. British Journal of Pharmacology, 142(7), 1171-1118. https://doi.org/10.1038/sj.bjp.0705807
Strassman, A. M., Raymond, S. A., & Burstein, R. (1996). Sensitization of meningeal sensory neurons and the origin of headaches. Nature, 384(6609), 560-564. https://doi.org/10.1038/384560a0
Summ, O., Holland, P. R., Akerman, S., & Goadsby, P. J. (2011). TRPV1 receptor blockade is ineffective in different in vivo models of migraine. Cephalalgia, 31(2), 172-180. https://doi.org/10.1177/0333102410375626
Takano, T., Tian, G. F., Peng, W., Lou, N., Lovatt, D., Hansen, A. J., Kasischke, K. A., & Nedergaard, M. (2007). Cortical spreading depression causes and coincides with tissue hypoxia. Nature Neuroscience, 10(6), 754-762. https://doi.org/10.1038/nn1902
Tallaksen-Greene, S. J., Young, A. B., Penney, J. B., & Beitz, A. J. (1992). Excitatory amino acid binding sites in the trigeminal principal sensory and spinal trigeminal nuclei of the rat. Neuroscience Letters, 141(1), 79-83. https://doi.org/10.1016/0304-3940(92)90339-9
Tepper, S. J., Krege, J. H., Lombard, L., Asafu-Adjei, J. K., Dowsett, S. A., Raskin, J., Buchanan, A. S., & Friedman, D. I. (2019). Characterization of dizziness after lasmiditan usage: Findings from the SAMURAI and SPARTAN acute migraine treatment randomized trials. Headache, 59(7), 1052-1062. https://doi.org/10.1111/head.13544 Erratum in: Headache, 2019 Nov, 59(10), 1875.
Tfelt-Hansen, P., Standnes, B., Kangasneimi, P., Hakkarainen, H., & Olesen, J. (1984). Timolol vs propranolol vs placebo in common migraine prophylaxis: A double-blind multicenter trial. Acute Neurologica Scandinavica, 69(1), 1-8. https://doi.org/10.1111/j.1600-0404.1984.tb07772.x
Tronvik, E., Stovner, L. J., Helde, G., Sand, T., & Bovim, G. (2003). Prophylactic treatment of migraine with an angiotensin II receptor blocker: A randomized controlled trial. JAMA, 289(1), 65-69. https://doi.org/10.1001/jama.289.1.65
Turner, L. C., Molgaard, C. A., Gardner, C. H., Rothrock, J. F., & Stang, P. E. (1995). Migraine trigger factors in a non-clinical Mexican-American population in San Diego county: Implications for etiology. Cephalalgia, 15(6), 523-530. https://doi.org/10.1046/j.1468-2982.1995.1506523.x
Van Reempts, J., Borgers, M., Van Dael, L., Van Eyndhoven, J., & Van De Ven, M. (1983). Protection with flunarizine against hypoxic-ischaemic damage of the rat cerebral cortex. A quantitative morphologic assessment. Archives Internationales de Pharmacodynamie et de Thérapie, 262(1), 76-88.
Vinson, D. R. (2002). Treatment patterns of isolated benign headache in US emergency departments. Annals of Emergency Medicine, 39(3), 215-222. https://doi.org/10.1067/mem.2002.121400
Wang, T., Chen, N., Zhan, W., Liu, J., Zhang, J., Liu, Q., Huang, H., He, L., Zhang, J., & Gong, Q. (2015). Altered effective connectivity of posterior thalamus in migraine with cutaneous allodynia: A resting-state fMRI study with Granger causality analysis. The Journal of Headache and Pain, 17, 17. https://doi.org/10.1186/s10194-016-0610-4
Wang, X., Li, W. G., Yu, Y., Xiao, X., Cheng, J., Zeng, W. Z., Peng, Z., Zhu, M. X., & Xu, T. L. (2013). Serotonin facilitates peripheral pain sensitivity in a manner that depends on the nonproton ligand sensing domain of ASIC3 channel. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 33(10), 4265-4279. https://doi.org/10.1523/JNEUROSCI.3376-12.2013
Westergaard, M. L., Lau, C. J., Allesøe, K., Gjendal, S. T., & Jensen, R. H. (2020). Monitoring chronic headache and medication-overuse headache prevalence in Denmark. Cephalalgia, 40(1), 6-18. https://doi.org/10.1177/0333102419876909
Wrobel Goldberg, S., & Silberstein, S. D. (2015). Targeting CGRP: A new era for migraine treatment. CNS Drugs, 29(6), 443-452. https://doi.org/10.1007/s40263-015-0253-z
Wu, L. J., Duan, B., Mei, Y. D., Gao, J., Chen, J. G., Zhuo, M., Xu, L., Wu, M., & Xu, T. L. (2004). Characterization of acid-sensing ion channels in dorsal horn neurons of rat spinal cord. The Journal of Biological Chemistry, 279(42), 43716-43724. https://doi.org/10.1074/jbc.M403557200
Yoshiyama, M., Omura, T., Takeuchi, K., Kim, S., Shimada, K., Yamagishi, H., Teragaki, M., Akioka, K., Iwao, H., & Yoshikawa, J. (2001). Angiotensin blockade inhibits increased JNKs, AP-1 and NF-κB DNA-binding activities in myocardial infarcted rats. Journal of Molecular and Cellular Cardiology, 33(4), 799-810. https://doi.org/10.1006/jmcc.2001.1351
Younis, S., Christensen, C. E., Toft, N. M., Søborg, T., Amin, F. M., Hougaard, A., & Ashina, M. (2019). Investigation of distinct molecular pathways in migraine induction using calcitonin gene-related peptide and sildenafil. Cephalalgia, 39(14), 1776-1788. https://doi.org/10.1177/0333102419882474